Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics.
A recent study published by RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski in the journal JGH Open: An open access journal of gastroenterology and hepatology, has shown that only ciprofloxacin displayed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals.
The research team concluded that further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.
The paper is available by clicking here.
More RSI News
RSI Provides Technical Advice and Review to Vietnam Partners and on-site Climate Support for Workshop
Engineers Canada is a partner with the German development agency Deutsche Gesellschaft für Internationale Zusammenarbeit GmbH (GIZ) in the execution of their Enhanced Climate Services…
Neil Comer to present at OPTrust Climate Change Symposium
The OPTrust Climate Change Symposium being held NOVEMBER 19-20, 2018 in TORONTO offers an opportunity to provide new insights into how to face climate change…
Emma Hartnett 2018 recipient of Center for Produce Safety (CPS) Research Award
CPS has recently announced 13 new research awards totaling a little over $2.6 million. The awards are for research projects directed at answering critical questions…
Best Practices for Consideration of the Effects of Climate Change in Project-Level Assessments
Risk Sciences International (RSI) is pleased to announce in collaboration with the Ontario Centre for Climate Impacts and Adaptation Resources (OCCIAR), the public release of…